Jasper Therapeutics (NASDAQ:JSPR) Now Covered by Analysts at Evercore ISI

Evercore ISI assumed coverage on shares of Jasper Therapeutics (NASDAQ:JSPR - Free Report) in a research report report published on Wednesday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $65.00 price objective on the stock.

JSPR has been the subject of several other research reports. Oppenheimer reiterated an outperform rating and set a $80.00 price objective on shares of Jasper Therapeutics in a report on Thursday, March 7th. TD Cowen assumed coverage on Jasper Therapeutics in a research note on Monday, March 18th. They issued an outperform rating for the company. Finally, Royal Bank of Canada assumed coverage on Jasper Therapeutics in a research note on Thursday, March 28th. They issued an outperform rating and a $70.00 target price for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of Buy and a consensus price target of $64.17.

Jasper Therapeutics Price Performance

NASDAQ JSPR traded up $0.90 during midday trading on Wednesday, hitting $27.10. 63,730 shares of the company traded hands, compared to its average volume of 130,202. The company has a market cap of $408.13 million, a PE ratio of -4.37 and a beta of 2.22. The company's 50-day simple moving average is $21.45 and its 200-day simple moving average is $12.15. Jasper Therapeutics has a 52 week low of $4.00 and a 52 week high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last announced its earnings results on Monday, March 4th. The company reported ($1.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.65) by $0.15. On average, research analysts predict that Jasper Therapeutics will post -5 earnings per share for the current year.

Insiders Place Their Bets

In related news, major shareholder Velan Capital Investment Manag purchased 350,000 shares of the business's stock in a transaction on Thursday, February 8th. The shares were bought at an average cost of $12.95 per share, with a total value of $4,532,500.00. Following the transaction, the insider now owns 1,188,500 shares of the company's stock, valued at $15,391,075. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Jasper Therapeutics

A number of institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC acquired a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $39,000. State Street Corp grew its position in shares of Jasper Therapeutics by 51.2% during the 2nd quarter. State Street Corp now owns 32,884 shares of the company's stock valued at $63,000 after acquiring an additional 11,132 shares during the period. Gries Financial LLC acquired a new stake in shares of Jasper Therapeutics during the 2nd quarter valued at about $33,000. UBS Group AG grew its position in shares of Jasper Therapeutics by 14.6% during the 4th quarter. UBS Group AG now owns 215,521 shares of the company's stock valued at $103,000 after acquiring an additional 27,495 shares during the period. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $67,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation.